Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

Author： Farfan-Portet María-Isabel   Gerkens Sophie   Lepage-Nefkens Isabelle   Vinck Irmgard   Hulstaert Frank  

Publisher： Springer Publishing Company

ISSN： 1618-7598

Source： The European Journal of Health Economics, Vol.15, Iss.3, 2014-04, pp. : 223-228

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cost‐containment and Financing the Long‐term Care of the Elderly

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 36, Iss. 4, 1988-04 ,pp. : 355-361

John Wiley & Sons Inc

Access to resources Recommend Favorite

CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL

By  

International Journal of Technology Assessment in Health Care, Vol. 33, Iss. 2, 2017-07 ,pp. : 199-205

Cambridge University Press

Access to resources Recommend Favorite

Cost Containment—Ethical Implications

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 40, Iss. 4, 1992-04 ,pp. : 413-416

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost Containment and the Elderly: Conflict or Challenge?

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 36, Iss. 1, 1988-01 ,pp. : 68-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Strategies for health care cost containment in 2013

By DiPersio Linda  

Journal of Communication In Healthcare, Vol. 6, Iss. 1, 2013-03 ,pp. : 1-2

Maney Publishing

Access to resources Recommend Favorite